Buspirone treatment of alcoholism: Age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking

Alcoholism: Clinical and Experimental Research

Volumn 23, Issue 2, 1999, Pages 272-278

  George, David T ^a,b   Rawlings, Robert ^a   Eckardt, Michael J ^b   Phillips, Monte J ^a   Shoaf, Susan E ^a   Linnoila, Markku ^a  

^a Laboratory of Clinical Studies (JCU   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol Treatment; Alcoholism; CSF 5HIAA; CSF HVA

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BUSPIRONE; HOMOVANILLIC ACID; PLACEBO; SEROTONIN 1A AGONIST;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE METABOLISM; DRINKING BEHAVIOR; HUMAN; MALE; NEUROTRANSMISSION; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONIN METABOLISM; TREATMENT OUTCOME;

EID: 0033061445     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1999.tb04110.x     Document Type: Article

References (65)

1. LeMarquand D, Pihl RO, Benkelfat C: Serotonin and alcohol intake, abuse, and dependence: Clinical evidence. Biol Psychiatry 36:326-337, 1994
2. Myers RD, Veale WL: Alcohol preference in the rat: Reduction following depletion of brain serotonin. Science 1469-1471, 1968
3. Rockman GE, Amit Z, Brown ZW, Bourque C, Ogren S-O: An investigation of the mechanisms of action of 5-hydroxytryptamine in the suppression of ethanol intake. Neuropharmacology 21:341-347, 1982
4. Lu M-R, Wagner GC, Fisher H: Ethanol consumption following acute fenfluramine, fluoxetine, and dietary tryptophan. Pharmacol Biochem Behav 44:931-937, 1993
5. Meert TF: Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 28:157-170, 1993
6. Melchior CL, Myers RD: Genetic differences in ethanol drinking of the rat following injection of 6-OHDA, 5,6-DHT or 5,7-DHT into the cerebral ventricles. Pharmacol Biochem Behav 5:63-72, 1976
7. Parvez H, Nevo I, Elisabeth P, Parvez S, Burov Y, Nagatsu T: Role of central 5-HT neurons upon predisposition to alcohol intake. Neuroendocrinol Lett 11:83-88, 1989
8. Rezvani AH, Overstreet DH, Janowsky DS: Genetic serotonin deficiency and alcohol preference in the fawn hooded rats. Alcohol Alcohol 25:573-575, 1990
9. Gongwer MA, Murphy JM, McBride WJ, Lumeng L, Li T-K: Regional brain contents of serotonin, dopamine and their metabolites in the selectively bred high- and low-alcohol drinking lines of rats. Alcohol 6:317-320, 1989
10. McBride WJ, Bodart B, Lumeng L, Li T-K: Association between low contents of dopamine and serotonin in the nucleus accumbens and high alcohol preference. Alcohol Clin Exp Res 19:1420-1422, 1995
11. Korpi ER, Paivarinta P, Abi-Dargham A, Honkanen A, Laruelle M, Tuominen K, Hilakivi LA: Binding of serotonergic ligands to brain membranes of alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol 9:369-374, 1992
12. Ballenger JC, Goodwin FK, Major LF, Brown GL: Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 36:224-227, 1979
13. Banki CM: Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Transm 50:89-101, 1981
14. Takahashi S, Yamane H, Kondo H, Tani N, Kato N: CSF monoamine metabolites in alcoholism: A comparative study with depression. Folia Psychiatr Neurol Jap 28:347-354, 1974
15. Rosenthal NE, Davenport Y, Cowdry RW, Webster MH, Goodwin FK: Monoamine metabolites in cerebrospinal fluid of depressive subgroups. Psychiatry Res 2:113-119, 1980
16. Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS: Age of alcoholism onset. II. Relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry 46:231-236, 1989
17. Fils-Aime ML, Eckardt MJ, George DT, Brown GL, Mefford I, Linnoila M: Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry 53:211-216, 1996
18. George DT, Benkelfat C, Rawlings RR, Eckardt MJ, Phillips MJ, Nutt DJ, Wynne D, Murphy DL, Linnoila M: Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects. Am J Psychiatry 154:81-87, 1997
19. Tabakoff B, Hoffman PL: Neurochemical effects of alcohol, in Miller F (ed): Clinical Textbook of Addictive Disorders, 1996, pp 501-525
20. George DT, Lindquist T, Rawlings RR, Eckardt MJ, Moss H, Mathis C, Martin PR, Linnoila M: Pharmacologic maintenance of abstinence in patients with alcoholism: No efficacy of 5-hydroxytryptophan or levodopa. Clin Pharmacol Ther 52:553-560, 1992
21. Naranjo CA, Sellers EM, Lawrin MO: Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry 47(Suppl.):16-22, 1986
22. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N: Placeblo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152:3:391-397, 1995
23. Routledge C, Gurling J, Ashworth-Preece MA, Dourish CT: Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol 276:281-284, 1995
24. Schreiber R, De Vry J: Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol 249:341-351, 1993
25. Fernandez-Guasti A, Lopez-Rubalcava C, Perez-Urizar J, Castaneda-Hernandez G: Evidence for a postsynaptic action of the serotonergic anxiolytics: Ipsapirone, indorenate and buspirone. Brain Res Bull 28:497-501, 1992
26. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM: Cellular localization of the 5-HT-1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35-46, 1996
27. Sprouse JS, Aghajanian GK: Responses of hippocampal pyramidal cells to putative serotonin 5-HT-1A and 5-HT-1B agonists: A comparative study with dorsal raphe neurons. Neuropharmacology 27:707-715, 1988
28. Blier P, De Montigny C: Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse 1:470-480, 1987
29. Kostowski W, Dyr W: Effects of 5-HT-1A receptor agonists on ethanol preference in the rat. Alcohol 9:283-286, 1992
30. Hedlund L, Wahlstrom G: Buspirone as an inhibitor of voluntary ethanol intake in male rats. Alcohol Alcohol 31:149-156, 1996
31. Collins DM, Myers RD: Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 4:49-56, 1987
32. Bruno F: Buspirone treatment of alcohol patients. Psychopathology 22:49-59, 1989
33. Tollefson GD, Montague-Clouse J, Tollefson SL: Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 12:19-26, 1992
34. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ: Buspirone treatment of anxious alcoholics. Arch Gen Psychiatry 51:720-731, 1994
35. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3-rev. Washington, D.C., American Psychiatric Association, 1987
36. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria (RDC) of a Selected Group of Functional Disorders, ed 3-updated. New York, Biometrics Research, New York State Psychiatry Institute, 1981
37. Endicott J, Spitzer RL: A diagnostic interview. The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35:837-844, 1978
38. Selzer ML: The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. Am J Psychiatry 127:1653-1658, 1971
39. Mayfield D, McLeod G, Hall P: The CAGE questionnaire: Validation of a new alcoholism screening instrument. Am J Psychiatry 131: 1121-1123, 1974
40. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296, 1967
41. Spielberger CD, Gorsuch RL, Lushene RD: Test Manual for the State-Trait Anxiety Inventory. Palo Alto, CA, Consulting Psychologists Press, 1970
42. Eckardt MJ, Parker ES, Noble EP, Feldman DJ, Gottschalk LA: Relationship between neuropsychological performance and alcohol consumption in alcoholics. Biol Psychiatry 13:551-564, 1978
43. Polinsky RJ, Brown RT, Burns RS, Harvey-White J, Kopin IJ: Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomie failure. J Neur Neurosurg Psych 51:914-919, 1988
44. Gammans RE, Mayol RF, Labudde JA: Metabolism and disposition of buspirone. Am J Med 80(Suppl. 3B):41-51, 1986
45. Statesoft, Inc.: STATISTICA for Windows (Volumes I-III). Tulsa, Statesoft, Inc., 1994
46. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A: A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16:1007-1013, 1992
47. Malec E, Malec T, Gagne MA, Dongier M: Buspirone in the treatment of alcohol dependence: A placebo-controlled trial. Alcohol Clin Exp Res 20:307-312, 1996
48. von Knorring L, Palm U, Andersson H-E: Relationship between treatment outcome and subtype of alcoholism in men. J Stud Alcohol 46:388-391, 1985
49. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B: Types of alcoholics. I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 49:599-608, 1992
50. Wise RA, Rompre P-P: Brain dopamine and reward. Ann Rev Psychol 40:191-225, 1989
51. Kelley AE, Delfs JM: Dopamine and conditioned reinforcement. II. Contrasting effects of amphetamine microinjection into the nucleus accumbens with peptide microinjection into the ventral tegmental area. Psychopharmacology 103:197-203, 1991
52. Balldin JI, Berggren UC, Lindstedt G: Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcohol Clin Exp Res 16:71-74, 1992
53. Balldin J, Berggren U, Lindstedt G, Sundkler A: Further neuroendocrine evidence for reduced D2 dopamine receptor function in alcoholism. Drug Alcohol Depend 32:159-162, 1993
54. Dettling M, Heinz A, Dufeu P, Rommelspacher H, Graf K-J, Schmidt LG: Dopaminergic responsivity in alcoholism: Trait, state, or residual marker? Am J Psychiatry 152:1317-1321, 1995
55. Farren CK, Clare AW, Ziedonis D, Hameedi FA, Dinan TG: Evidence for reduced dopamine D2 receptor sensitivity in postwithdrawal alcoholics. Alcohol Clin Exp Res 19:1520-1524, 1995
56. Heinz A, Lichtenberg-Kraag B, Baum S, Graf K, Kruger F, Dettling M, Rommelspacher H: Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome. J Neural Transm 102:149-157, 1995
57. Tiihonen J, Kuikka J, Bergstrom K, Hakola P, Karhu J, Ryynanen O-P, Fohr J: Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Natl Med 1:654-657, 1995
58. Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ: Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiat Res 20:175-193, 1986
59. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia: Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 50:599-605, 1993
60. Howell LL, Byrd LD: Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275:1551-1559, 1995
61. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476, 1996
62. Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA: Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology 112:S60-S67, 1993
63. Wozniak KM, Pert A, Linnoila M: Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol 187:287-289, 1990
64. Campbell AD, McBride WJ: Serotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 51:835-842, 1995
65. Grant KA: The role of 5-HT-3 receptors in drug dependence. Drug Alcohol Depend 38:155-171, 1995